% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fonseca:12540,
      author       = {Fonseca, F.C. and Uhlenbruck, S. and Nédélec, R. and
                      Sebold, D. and Buchkremer, H. P.},
      title        = {{T}emperature and {B}ias {E}ffects on {S}puttered {C}eria
                      {D}iffusion {B}arriers for {S}olid {O}xide {F}uel {C}ells},
      journal      = {Journal of the Electrochemical Society},
      volume       = {157},
      issn         = {0013-4651},
      address      = {Pennington, NJ},
      publisher    = {Electrochemical Society},
      reportid     = {PreJuSER-12540},
      pages        = {B1515 - B1519},
      year         = {2010},
      note         = {F.C.F. is thankful for the Brazilian agencies FAPESP
                      (2007/08686-8) and CNPq (306422/2007-7). Thanks also to F.
                      Vondahlen for helping us with PVD depositions and W. Herzhof
                      and K. Portulidou for sample supplying/cathode depositions.},
      abstract     = {This open-label extension evaluated the long-term efficacy
                      and tolerability of rufinamide in patients with
                      Lennox-Gastaut syndrome (LGS) who had previously completed a
                      12-week double-blind study.In total, 124 patients (aged 4-37
                      years), receiving 1-3 concomitant antiepileptic drugs, were
                      treated with rufinamide approximately 25-60 mg/kg/day.
                      Efficacy was assessed by seizure frequency; tolerability by
                      adverse events (AEs) and laboratory tests.Overall, patients
                      were treated with rufinamide for a median (range) of 432
                      (10-1149) days. Reductions in seizure frequency were
                      observed throughout the study; during the last 12 months of
                      treatment, $41.0\%$ and $47.9\%$ of patients had > or =
                      $50\%$ reduction in total and tonic-atonic seizure
                      frequency, respectively. The most common AEs were vomiting
                      $(30.6\%)$ and pyrexia $(25.8\%).In$ this open-label
                      extension, rufinamide appeared to be an effective long-term
                      adjunctive therapy for the treatment of LGS-associated
                      seizures in children and young adults.},
      keywords     = {J (WoSType)},
      cin          = {IEK-1},
      ddc          = {540},
      cid          = {I:(DE-Juel1)IEK-1-20101013},
      pnm          = {Rationelle Energieumwandlung / SOFC - Solid Oxide Fuel Cell
                      (SOFC-20140602)},
      pid          = {G:(DE-Juel1)FUEK402 / G:(DE-Juel1)SOFC-20140602},
      shelfmark    = {Electrochemistry / Materials Science, Coatings $\&$ Films},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000281306900040},
      doi          = {10.1149/1.3476296},
      url          = {https://juser.fz-juelich.de/record/12540},
}